Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer | Zendy

Sinja Taavitsainen | Zendy; Matti Annala | Zendy; Elisa M. Ledet | Zendy; Kevin Beja | Zendy; Patrick J. O. Miller | Zendy; Marcus W. Moses | Zendy; Matti Nykter | Zendy; Kim N. | Zendy; Oliver Sartor | Zendy; Alexander W. Wyatt | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer

Author(s) -

Sinja Taavitsainen,

Matti Annala,

Elisa M. Ledet,

Kevin Beja,

Patrick J. O. Miller,

Marcus W. Moses,

Matti Nykter,

Kim N.,

Oliver Sartor,

Alexander W. Wyatt

Publication year - 2019

Publication title -

jco precision oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.405

H-Index - 22

ISSN - 2473-4284

DOI - 10.1200/po.19.00014

Subject(s) - prostate cancer , concordance , somatic cell , cold pcr , germline mutation , germline , biology , digital polymerase chain reaction , allele , cancer research , dna sequencing , mutation , gene , cancer , genetics , oncology , medicine , point mutation , polymerase chain reaction

Circulating tumor DNA (ctDNA) sequencing provides a minimally invasive method for tumor molecular stratification. Commercial ctDNA sequencing is increasingly used in the clinic, but its accuracy in metastatic prostate cancer is untested. We compared the commercial Guardant360 ctDNA test against an academic sequencing approach for profiling metastatic prostate cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research